Catalent Inc.

Catalent, Inc. operates as a holding company. The firm engages in the provision of delivery technologies and development solutions for drugs, biologics and consumer and animal health products. It operates through the following segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery and Clinical Supply Services. The Softgel Technologies segment formulates, develops and manufactures services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufactures services for blow-fill-seal unit doses, prefilled syringes, vials and cartridges, analytical development and testing services for large molecules, inhaled products for delivery via metered dose inhalers, dry powder inhalers and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.